Core Insights - Predictive Oncology Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000, allowing its shares to continue trading on the Nasdaq Capital Market under the ticker "POAI" [1] - The company is focusing on a digital asset strategy centered around the Aethir network's native utility token, ATH, which aims to create a Strategic Compute Reserve [3] Company Overview - Predictive Oncology utilizes AI and machine learning to enhance early drug discovery, particularly for cancer treatment, with its AI platform, PEDAL, achieving a 92% accuracy rate in predicting tumor responses to drug compounds [2] - The company maintains a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive resources for drug discovery [2] Digital Asset Strategy - The digital asset treasury strategy involves holding ATH tokens, positioning the company as an operator within the Aethir ecosystem, which aims to democratize access to AI infrastructure globally [3]

Core Insights - Predictive Oncology Inc. has appointed Shawn Matthews, Thomas McLaughlin, and Sara Turken to its leadership team and Board of Directors to support its new digital asset treasury strategy focused on the Aethir (ATH) token [1][2][3] Leadership Appointments - Shawn Matthews, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, joins the Board of Directors [2][3] - Thomas McLaughlin, CIO of DNA Holdings Venture, Inc., is appointed as Chief Investment Officer [2][4] - Sara Turken, JD, a biopharmaceutical veteran, is appointed as General Counsel [2][5] Strategic Focus - The company is leveraging its AI-driven drug discovery capabilities to implement an innovative digital treasury asset strategy, which aims to address its AI requirements and capitalize on the growing global need for AI infrastructure [3][8] - Predictive Oncology operates a digital asset treasury focused on the Aethir (ATH) token, creating the world's first Strategic Compute Reserve [8] Company Background - Predictive Oncology utilizes AI and machine learning to expedite early drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [6][7] - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [7]